Mylan picks 3M to manufacture its generic Advair inhaler for U.K. market

Mylan ($MYL) said on Monday that it had started selling in the U.K. its generic of GlaxoSmithKline's ($GSK) asthma treatment Seretide Evohaler, known better in the U.S. as Advair. Mylan said the inhalers will be assembled and packaged for it by 3M Drug Delivery Systems at the 3M ($MMM) manufacturing facility in Loughborough, U.K. There are already other generics in the U.K. of the blockbuster, which in 2013 turned in sales of $8.6 billion. The growing competition has taken a big bite out of GSK's revenues, leading it to make layoffs in the U.S. Release | More

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.